Showing results (1011-1020 of 6,317) with videos related to

Sort By:
Pageof 632
Diabetes, Obesity & Metabolism|May 27, 2020
Greater variability in lipid measurements associated with cardiovascular disease and mortality: A 10-year diabetes cohort studyEric Y F Wan, Esther Y T Yu, Weng Y Chin, et al.
Diabetes, Obesity & Metabolism|June 2, 2020
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysisChrysanthi Mantsiou, Thomas Karagiannis, Panagiota Kakotrichi, et al.
Diabetes, Obesity & Metabolism|April 28, 2021
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trialsAnnemarie B van der Aart-van der Beek, David Cherney, Gozewijn D Laverman, et al.
Diabetes, Obesity & Metabolism|May 22, 2020
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trialClare Arnott, Yuli Huang, Brendon L Neuen, et al.
Diabetes, Obesity & Metabolism|August 11, 2021
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled studyKirsten Thiele, Matthias Rau, Niels-Ulrik K Hartmann, et al.
Diabetes, Obesity & Metabolism|August 13, 2021
Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trialIda K B Rasmussen, Emilie H Zobel, Rasmus S Ripa, et al.
Diabetes, Obesity & Metabolism|August 13, 2021
A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications-What the non-specialist needs to knowMark D Muthiah, Ng Cheng Han, Arun J Sanyal
Diabetes, Obesity & Metabolism|August 13, 2021
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulinYu Pei, Bue R Agner, Bin Luo, et al.
Diabetes, Obesity & Metabolism|August 5, 2021
Exendin(9-39)NH2 : Recommendations for clinical use based on a systematic literature reviewLaerke Smidt Gasbjerg, Emilie Johanning Bari, Mikkel Christensen, et al.
Diabetes, Obesity & Metabolism|May 15, 2020
Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes with two or more components of metabolic syndrome over 24 weeksSin Gon Kim, Kyoung Jin Kim, Kun Ho Yoon, et al.
Pageof 632